The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Promising early-phase trials exploiting MTAP deletion in mesothelioma
Paolo Bironzo, MD, PhD, University of Turin, Turin, Italy, comments on promising early-phase trial updates in mesothelioma. Exploiting MTAP deletions through PRMT5 and MTAP inhibitors have been touted as another future treatment avenue, with multiple trials currently exploring these agents in mesothelioma. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
